MedPath

Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

Phase 3
Terminated
Conditions
Schizophrenia
Interventions
Drug: Olanzapine, Omega 3, Vitamin E+C
Registration Number
NCT00211562
Lead Sponsor
Augusta University
Brief Summary

This research study helps to demonstrate that adding vitamins and fats (nutritional supplements) to a diet will help reduce body weight and improve the lipid profile. This will be done by examining the body weight and chemicals in the blood. The chemicals are the result of the brain using the fat that subjects eat in their diet. Some medications may also change the amount of these chemicals in a person's blood.

Detailed Description

To demonstrate that supplementation of antioxidants and omega-3 fatty acids will improve clinical outcome including cognitive performance in olanzapine treated patients.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Age 18 to 55
  • VA outpatient
  • Diagnosis of schizophrenia by DSM-IV criteria
  • Active treatment with olanzapine
  • Medically healthy
Exclusion Criteria
  • Diagnosis of MR
  • MMSE score of < 26
  • Not on a stable dose of olanzapine

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Omega 3Olanzapine, Omega 3, Vitamin E+C-
Vitamin E +COlanzapine, Omega 3, Vitamin E+C-
OlanzapineOlanzapine, Omega 3, Vitamin E+C-
Primary Outcome Measures
NameTimeMethod
PANSS2003-2006

Study completed in 2006. PI no longer with the institution. Study was closed accordingly to the HAC.

BMI2003-2006

BMI match height and weight.

Blood samples2003-2006

Samples analyzed, PI analyzed and published. PI no longer with the institution.

Secondary Outcome Measures
NameTimeMethod
Cognitive assessments2003-2006

BACS assessment. Data analyzed and published by the PI.

Trial Locations

Locations (1)

VA Medical Center

🇺🇸

Augusta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath